John F. Ginascol's Insider Trades & SAST Disclosures
John F. Ginascol's most recent trade in Abbott Laboratories was a trade of 6,859 Common shares without par value done at an average price of $99.8 . Disclosure was reported to the exchange on Feb. 28, 2023.
Add Superstar Alert
Share
Note
This is a custom search result for pattern John F. Ginascol.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Abbott Laboratories | John F. Ginascol | EXECUTIVE VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 99.77 per share. | 28 Feb 2023 | 6,859 | 119,323 (0%) | 0% | 99.8 | 684,322 | Common shares without par value |
| Abbott Laboratories | John F. Ginascol | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 100.70 per share. | 28 Feb 2023 | 943 | 118,380 (0%) | 0% | 100.7 | 94,960 | Common shares without par value |
| Abbott Laboratories | John F. Ginascol | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 56,275 | 56,275 | - | - | Option (right to buy) | |
| Abbott Laboratories | John F. Ginascol | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 14,270 | 126,182 (0%) | 0% | 0 | Common shares without par value | |
| Abbott Laboratories | John F. Ginascol | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 112.32 per share. | 13 Dec 2022 | 11,000 | 111,912 (0%) | 0% | 112.3 | 1,235,520 | Common shares without par value |
| Abbott Laboratories | John F. Ginascol | EXECUTIVE VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 117.51 per share. | 03 Jun 2022 | 1,768 | 122,912 (0%) | 0% | 117.5 | 207,758 | Common shares without par value |
| Abbott Laboratories | John F. Ginascol | EXECUTIVE VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 122.41 per share. | 28 Feb 2022 | 5,876 | 125,045 (0%) | 0% | 122.4 | 719,281 | Common shares without par value |
| Abbott Laboratories | John F. Ginascol | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 118.16 per share. | 28 Feb 2022 | 365 | 124,680 (0%) | 0% | 118.2 | 43,128 | Common shares without par value |
| Abbott Laboratories | John F. Ginascol | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 80,380 | 80,380 | - | - | Option (right to buy) | |
| Abbott Laboratories | John F. Ginascol | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 17,247 | 130,921 (0%) | 0% | 0 | Common shares without par value | |
| Abbott Laboratories | John F. Ginascol | EXECUTIVE VICE PRESIDENT | 27 Oct 2021 | 45,709 | 143,262 (0%) | 0% | 47 | 2,148,323 | Common shares without par value | |
| Abbott Laboratories | John F. Ginascol | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Oct 2021 | 45,709 | 0 | - | - | Option (right to buy) | |
| Abbott Laboratories | John F. Ginascol | EXECUTIVE VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 128.13 per share. | 27 Oct 2021 | 29,588 | 113,674 (0%) | 0% | 128.1 | 3,791,110 | Common shares without par value |
| Abbott Laboratories | John F. Ginascol | EXECUTIVE VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 106.90 per share. | 03 Jun 2021 | 1,768 | 97,553 (0%) | 0% | 106.9 | 188,999 | Common shares without par value |
| Abbott Laboratories | John F. Ginascol | EXECUTIVE VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 121.58 per share. | 26 Feb 2021 | 4,736 | 99,673 (0%) | 0% | 121.6 | 575,803 | Common shares without par value |
| Abbott Laboratories | John F. Ginascol | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 120.61 per share. | 26 Feb 2021 | 352 | 99,321 (0%) | 0% | 120.6 | 42,455 | Common shares without par value |
| Abbott Laboratories | John F. Ginascol | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2021 | 78,966 | 78,966 | - | - | Option (right to buy) | |
| Abbott Laboratories | John F. Ginascol | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2021 | 15,406 | 104,409 (0%) | 0% | 0 | Common shares without par value | |
| Abbott Laboratories | John F. Ginascol | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 109.47 per share. | 01 Sep 2020 | 47,772 | 89,003 (0%) | 0% | 109.5 | 5,229,601 | Common shares without par value |
| Abbott Laboratories | John F. Ginascol | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2020 | 39,953 | 0 | - | - | Option (right to buy) | |
| Abbott Laboratories | John F. Ginascol | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 44.40 per share. | 01 Sep 2020 | 39,953 | 136,775 (0%) | 0% | 44.4 | 1,773,913 | Common shares without par value |
| Abbott Laboratories | John F. Ginascol | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2020 | 20,133 | 0 | - | - | Option (right to buy) | |
| Abbott Laboratories | John F. Ginascol | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.40 per share. | 01 Sep 2020 | 20,133 | 96,822 (0%) | 0% | 38.4 | 773,107 | Common shares without par value |
| Abbott Laboratories | John F. Ginascol | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2020 | 12,012 | 45,709 | - | - | Option (right to buy) | |
| Abbott Laboratories | John F. Ginascol | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.00 per share. | 01 Sep 2020 | 12,012 | 76,689 (0%) | 0% | 47 | 564,564 | Common shares without par value |
| Abbott Laboratories | John F. Ginascol | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 92.62 per share. | 03 Jun 2020 | 1,768 | 64,677 (0%) | 0% | 92.6 | 163,752 | Common shares without par value |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges